personalizing treatment of transfusion-dependent anemia in lr-mds
Published 1 month ago • 21 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
1:57
enhancing clinical care in lr-mds: managing symptomatic/transfusion-dependent anemia
-
1:18
the importance of treating anemia early to avoid transfusion-dependence in lr-mds
-
3:46
managing transfusion dependence in mds: lenalidomide, esas & defining a threshold for transfusion
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:05
unmet needs in lr-mds: managing anemia
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:21
unmet needs in lr-mds: rbc transfusion-dependence
-
16:42
management of treatment-naïve lr-mds
-
6:36
mds: low-risk disease treatment options
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
1:44
the standards for managing anemia in patients with mds
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
0:55
the role of rna modifications in mds and aml
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
2:43
novel therapies in the future of mds treatment
-
1:17
the curative potential of allosct in the treatment of hr-mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:43
reasons why there are fewer treatment options for mds patients and hope for the future
-
3:38
a new set of treatment options for low-risk mds
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment